Insulet's August 5 collapse was a durability repricing, and the bear case remains intact. Management cut FY2026 revenue-growth guidance to 20%-22% from 21%-23% because U.S. demand slowed more sharply than expected. That is a direct challenge to the Omnipod thesis, which depends on sustained high growth rather than one good quarter. We are selling PODD ahead of the October 29 earnings report because the market now needs proof that the core U.S. business can reaccelerate.
The business remains profitable, but the earnings mix has become less reassuring. Insulet produces a 71.1% gross margin, a 16.9% operating margin and a 95 Profitability sub-score within the TickerSpark Score. Yet trailing EPS growth is negative 41.2% and net-income growth is negative 40.9%, while the TickerSpark Score assigns only 55 to Growth and 30 to Momentum. At 24.86 times trailing earnings and 3.02 times sales, PODD is no longer priced like a flawless growth story, but it is not priced like a business whose U.S. trajectory has just become uncertain either.
Bulls have legitimate ammunition. Q2 revenue reached $801.7 million and beat consensus estimates, the company launched Omnipod 5 and Omnipod Discover in Spain, and the recent earnings record shows beats in seven of the last eight quarters. The analyst consensus also remains Buy, with 35 buy ratings against 12 holds and 3 sells. International expansion and strong product economics can keep the long-term franchise valuable, but they do not erase the immediate guidance reset: U.S. demand is the engine that just lost speed, and second-half growth is now expected to decelerate below 20%.
The trigger that changes our mind is a demonstrated U.S. reacceleration paired with restored confidence in execution. Until then, the 20% plunge is doing exactly what a repricing should do: forcing investors to pay less for a growth rate that management itself just marked down. Positioning remains bearish, and any rebound that fails near the broken moving-average trend is an exit opportunity rather than confirmation of a new bull run.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
